Health Care [ 10/12 ] | Pharmaceuticals [ 52/76 ]
NYSE | Common Stock
Merck & Co., Inc. operates as a healthcare company worldwide.
It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets.
The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 3, 26 | 2.04 Increased by +18.60% | 2.01 Increased by +1.47% |
| Oct 30, 25 | 2.58 Increased by +64.33% | 2.37 Increased by +8.86% |
| Jul 29, 25 | 2.13 Decreased by -6.58% | 2.03 Increased by +4.93% |
| Apr 24, 25 | 2.22 Increased by +7.25% | 2.14 Increased by +3.74% |
| Feb 4, 25 | 1.72 Increased by +5.63 K% | 1.67 Increased by +2.99% |
| Oct 31, 24 | 1.57 Decreased by -26.29% | 1.57 |
| Jul 30, 24 | 2.28 Increased by +210.68% | 2.15 Increased by +6.05% |
| Apr 25, 24 | 2.07 Increased by +47.86% | 1.88 Increased by +10.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 16.40 B Increased by +4.97% | 2.96 B Decreased by -20.84% | Increased by +18.07% Decreased by -24.58% |
| Sep 30, 25 | 17.28 B Increased by +3.72% | 5.79 B Increased by +83.24% | Increased by +33.49% Increased by +76.68% |
| Jun 30, 25 | 15.81 B Decreased by -1.90% | 4.43 B Decreased by -18.85% | Increased by +28.01% Decreased by -17.27% |
| Mar 31, 25 | 15.53 B Decreased by -1.56% | 5.08 B Increased by +6.66% | Increased by +32.71% Increased by +8.35% |
| Dec 31, 24 | 15.62 B Increased by +6.79% | 3.74 B Increased by +405.30% | Increased by +23.96% Increased by +385.88% |
| Sep 30, 24 | 16.66 B Increased by +4.35% | 3.16 B Decreased by -33.47% | Increased by +18.95% Decreased by -36.24% |
| Jun 30, 24 | 16.11 B Increased by +7.16% | 5.46 B Increased by +191.30% | Increased by +33.86% Increased by +185.19% |
| Mar 31, 24 | 15.78 B Increased by +8.89% | 4.76 B Increased by +68.81% | Increased by +30.19% Increased by +55.02% |